
Deutsche Bank praises AstraZeneca's lung drug data but rates shares 'sell' with a target of 11,500p.
Deutsche Bank acknowledged positive data from AstraZeneca's tozorakimab for chronic obstructive pulmonary disease (COPD), presented at the ERS conference, supporting the drug's commercial potential. Despite this, the bank maintained a 'sell' rating o...





